Summary slide.png (83.22 kB)

Long-Term Cost-Effectiveness Analyses of Empagliflozin versus Oral Semaglutide, in Addition to Metformin, For the Treatment of Type 2 Diabetes in the UK

media

posted on 2020-07-21, 08:58 authored by Mafalda Ramos, Michael H. Cummings, Anastasia Ustyugova, Syed I. Raza, Shamika U. de Silva, Mark Lamotte

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s13300-020-00883-1

Usage metrics

Read the peer-reviewed publication

Long-Term Cost-Effectiveness Analyses of Empagliflozin versus Oral Semaglutide, in Addition to Metformin, For the Treatment of Type 2 Diabetes in the UK

Diabetes Therapy

Keywords

Costs and cost analysis Cost-effectiveness Diabetes mellitus Empagliflozin GLP-1 receptor agonists Oral semaglutide SGLT-2 inhibitors Treatment intensification United Kingdom

Licence

CC BY-NC 4.0

Long-Term Cost-Effectiveness Analyses of Empagliflozin versus Oral Semaglutide, in Addition to Metformin, For the Treatment of Type 2 Diabetes in the UK

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports